FDG-PET/CT imaging parameters for predicting spontaneous regression of methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 09 2022
13 09 2022
Historique:
received:
15
01
2022
accepted:
02
09
2022
entrez:
13
9
2022
pubmed:
14
9
2022
medline:
16
9
2022
Statut:
epublish
Résumé
In this study, we investigated the usefulness of FDG-PET/CT for predicting spontaneous regression in methotrexate-associated lymphoproliferative disorder (MTX-LPD). Twenty patients with rheumatoid arthritis who were diagnosed with MTX-LPD were enrolled in the study. These patients were divided into those who showed spontaneous regression (SR group: ten patients) and those who received chemotherapy after discontinuation of MTX (CTx group: ten patients). Between-group differences in potential biomarkers were compared, including clinical markers at the onset of LPD [serum LDH and interleukin 2 receptor (sIL-2R)], change in absolute number of peripheral lymphocytes (ΔALC) over follow-up, and the FDG-PET/CT-derived parameters of maximum standardized uptake value (SUVmax), mean SUV (SUVmean), peak SUV (SUVpeak), sum of the metabolic tumor volume (MTVsum), and sum of total lesion glycolysis (TLGsum). The levels of sIL-2R, MTVsum, and TLGsum were significantly lower in the SR group than in the CTx group. In addition, ΔALC was higher in the SR group. In conclusion, MTV and TLG values measured by FDG-PET/CT may be suitable for use as predictors of SR in patients with MTX-LPD.
Identifiants
pubmed: 36100660
doi: 10.1038/s41598-022-19727-y
pii: 10.1038/s41598-022-19727-y
pmc: PMC9470546
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15367Informations de copyright
© 2022. The Author(s).
Références
J Nucl Med. 2006 Nov;47(11):1808-12
pubmed: 17079814
Ann Hematol. 2018 Sep;97(9):1611-1618
pubmed: 29713747
Rheumatology (Oxford). 2017 Jun 1;56(6):940-946
pubmed: 28165538
J Clin Exp Hematop. 2020 Jun 20;60(2):41-50
pubmed: 32404570
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1768-1772
pubmed: 31183636
BMC Cancer. 2016 Aug 15;16:635
pubmed: 27528380
Mol Imaging Biol. 2018 Feb;20(1):1-3
pubmed: 29181818
Contrast Media Mol Imaging. 2021 Nov 22;2021:7528971
pubmed: 34887713
PLoS One. 2014 Aug 27;9(8):e105682
pubmed: 25162396
Radiother Oncol. 2018 Oct;129(1):161-165
pubmed: 29108779
Clin Positron Imaging. 1999 May;2(3):159-171
pubmed: 14516540
Nucl Med Commun. 2021 Apr 1;42(4):437-443
pubmed: 33306638
Mod Rheumatol. 2018 Jan;28(1):1-8
pubmed: 28758827
Mod Rheumatol. 2022 Jan 5;32(1):24-31
pubmed: 33496194
J Radiat Res. 2016 Nov;57(6):655-661
pubmed: 27422935
Arthritis Rheum. 2003 Jun;48(6):1543-50
pubmed: 12794821
J Rheumatol. 1991 Nov;18(11):1741-3
pubmed: 1787499
Mod Rheumatol. 2017 Sep;27(5):773-777
pubmed: 27846761
Nucl Med Commun. 2020 Dec;41(12):1283-1290
pubmed: 32925828
Mod Rheumatol. 2015 Jul;25(4):579-84
pubmed: 25437196